# US 2012/0253102 A1 · External magnetic force for targeted cell delivery with enhanced cell retention

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2012/0253102 A1
- Document ID: US20120253102A1
- Status: Published application
- Kind: A1
- Application number: 13/504,747
- Filed: 2010-10-27
- Published: 2012-10-04
- Earliest claimed: 2009-10-27
- Assignees: Cedars-Sinai Medical Center
- Inventors: Eduardo Marban; Ke Cheng
- Web page: https://patentgrep.com/patent/US20120253102A1

## CPC

- A61N 2/002: {in combination with another treatment}
- A61M 25/0068: {Static characteristics of the catheter tip, e.g. shape, atraumatic tip, curved tip or tip structure}
- A61M 25/0082: {Catheter tip comprising a tool}
- A61M 25/04: in the body, e.g. expansible {(A61M25/10, A61M16/0488 take precedence)}
- A61M 25/10: Balloon catheters ({A61M25/0125 takes precedence; embolectomy A61B17/22032; retractors A61B17/02;} inflatable balloons for placing stents or stent-grafts A61F2/958 {; stomach balloons for treatment of obesity A61F5/0003; oesophagal tubes A61J15/00})
- A61N 2/06: using magnetic fields produced by permanent magnets (A61N2/12 takes precedence)
- A61M 25/0133: {Tip steering devices}
- A61N: ELECTROTHERAPY; MAGNETOTHERAPY; RADIATION THERAPY; ULTRASOUND THERAPY (measurement of bioelectric currents A61B; surgical instruments, devices or methods for transferring non-mechanical forms of energy to or from the body A61B18/00; anaesthetic apparatus in general A61M; incandescent lamps H01K; infrared radiators for heating H05B)
- A61M: DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY (introducing media into or onto the bodies of animals A61D7/00; means for inserting tampons A61F13/26; devices for administering food or medicines orally A61J; containers for collecting, storing or administering blood or medical fluids A61J1/05); DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY (surgery A61B; chemical aspects of surgical articles A61L); DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR {(Electrotherapy, e.g. producing anaesthesia by the use of alternating or intermittent currents A61N1/36021)}

## Abstract

Disclosed herein are compositions and methods for the improved delivery of cells to a target tissue. In some embodiments, the compositions comprise stem cells, in particular cardiac stem cells, and the target tissue is damaged or diseased cardiac tissue. In several embodiments, the methods, in combination with the compositions, yield enhanced delivery, retention, and/or engraftment of the cells into the target tissue, thereby inducing improved functional recovery.

## Claims

### Claim at position 1

-98. (canceled)

### Claim 99

A method for repairing damaged cardiac tissue in a patient comprising:
applying a magnetic field to a region of damaged cardiac tissue in a patient having damaged cardiac tissue,
wherein the application of the magnetic field targets to the region of damaged cardiac tissue a population of stem cells in the patient that have been magnetically labeled to form magnetically labeled stem cells,
wherein the magnetically labeled stem cells comprise stem cells labeled with magnetic particles linked to a first antibody portion and a second antibody portion,
wherein the first antibody portion is bound to a cell surface molecule on the stem cell and the second antibody portion is capable of binding to a cardiac tissue marker expressed in damaged cardiac tissue,
wherein the magnetic field and the second antibody portion enhance the retention and engraftment of the magnetically labeled stem cells to the region of damaged cardiac tissue; and
wherein the enhanced retention and engraftment of the magnetically labeled stem cells in the region of damaged cardiac tissue results in improved cardiac function, thereby repairing said damaged cardiac tissue.

### Claim 100 (depends on 99)

The method of claim 99, wherein the stem cells are bound to the magnetic label ex vivo.

### Claim 101 (depends on 99)

The method of claim 99, wherein the stem cells are bound to the magnetic label in vivo.

### Claim 102 (depends on 99)

The method of claim 99, wherein the first antibody portion and the second antibody portion are contained in a single bi-functional antibody.

### Claim 103 (depends on 99)

The method of claim 99, wherein the first antibody portion is contained on a first antibody and the second antibody portion is contained on a second antibody.

### Claim 104 (depends on 99)

The method of claim 99, wherein the magnetic field is applied while the patient's heart is actively contracting,
wherein the active contraction induces an efflux of the magnetically labeled stem cells away from the site of damaged cardiac tissue in the absence of the magnetic field; and
wherein the magnetic field counteracts the efflux.

### Claim 105 (depends on 99)

The method of claim 99, wherein the population of stem cells are cardiac stem cells.

### Claim 106 (depends on 105)

The method of claim 105, wherein the population of cardiac stem cells are cardiosphere-derived cells.

### Claim 107 (depends on 99)

The method of claim 99, wherein the first antibody portion is bound to the cell surface molecule selected from the group consisting of c-kit, CD-105, CD-90, and CD-31.

### Claim 108 (depends on 107)

The method of claim 107, wherein the first antibody portion is bound to the cell surface molecule CD-105.

### Claim 109

A composition comprising a population of magnetically labeled stem cells suitable for treating a patient with damaged cardiac tissue comprising:
a population of stem cells linked to magnetic particles,
wherein the magnetic particles are linked to a first antibody portion and a second antibody portion,
wherein the first antibody portion is bound to a cell surface molecule on the stem cell and the second antibody portion is capable of binding to a cardiac tissue marker expressed in damaged cardiac tissue;
wherein the population of magnetically labeled stem cells are capable of retention and engraftment in a region of damaged cardiac tissue which results in improved cardiac function, thereby repairing said damaged cardiac tissue.

### Claim 110 (depends on 109)

The composition of claim 109, wherein the first antibody portion and the second antibody portion are contained in a single bi-functional antibody.

### Claim 111 (depends on 109)

The composition of claim 109, wherein the first antibody portion is contained on a first antibody and the second antibody portion is contained on a second antibody.

### Claim 112 (depends on 109)

The composition of claim 109, wherein the population of stem cells are cardiac stem cells.

### Claim 113 (depends on 112)

The composition of claim 112, wherein the cardiac stem cells are cardiosphere-derived cells.

### Claim 114 (depends on 109)

The composition of claim 109, wherein the first antibody is bound to the cell surface molecule selected from the group consisting of c-kit, CD-105, CD-90, and CD-31.

### Claim 115 (depends on 114)

The composition of claim 114, wherein the first antibody is bound to the cell surface molecule CD-105.
